Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40722
Title: | Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT | Authors: | Spirito, Alessandro Valgimigli, Marco Cao, Davide Baber, Usman Mehta, Shamir R. Gibson, C. Michael Steg, Gabriel P. Sharma, Samin K. Goel, Ridhima Huber, Kurt Kunadian, Vijay Escaned, Javier Franzone, Anna Yaling, Han Collier, Timothy Kaul, Upendra Kornowski, Ran Krucoff, Mitchell Moliterno, David Sartori, Samantha Owen, Ruth Zhang, Zhongjie Dangas, George D. Kastrati, Adnan Angiolillo, Dominick J. Cohen, David J. VRANCKX, Pascal Windecker, Stephan Pocock, Stuart Mehran, Roxana |
Issue Date: | 2023 | Publisher: | ELSEVIER IRELAND LTD | Source: | International Journal of Cardiology, 383 , p. 24 -32 | Abstract: | Background: Biodegradable polymer biolimus-eluting stents (BP-BES) may be associated with better outcomes in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) compared to other current-generation limus-eluting stents (LES). Aims: To compare BP-BES with other current-generation LES in ACS patients undergoing PCI. Methods: We pooled individual data of Non-ST-segment elevation (NSTE)-ACS patients from two large ran-domized controlled trials (GLASSY and TWILIGHT). The BP-BES groups consisted mostly of GLASSY patients, while the control group (other current-generation LES) included exclusively TWILIGHT patients. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular death, myocardial infarc-tion, or stent thrombosis; the key secondary outcome was target-vessel failure (TVF). To account for trial design differences, outcomes were assessed at 3 months (short-term) and between 3 and 12 months (long-term) after PCI and subsequently pooled to estimate the 12-month hazards. Results: Of 7107 and 6053 NSTE-ACS patients included in the short-and long-term analysis, 32.7% and 36.5% received a BP-BES, respectively. Risk of MACE associated with BP-BES versus other LES was similar at short-term (1.1% vs 1.3%, adjusted HR 0.86, 95%CI 0.53-1.38), lower at long-term (1.7% vs 3.1%, adjusted HR 0.49, 95% CI 0.34-0.72), and lower in the entire 12-month period (pooled adjusted HR 0.61, 95%CI 0.45-0.82). The cu-mulative 12-month risk of TVF was reduced with BP-BES (adjusted HR 0.52, 95%CI 0.38-0.70). Conclusion: BP-BES was associated with lower 12-month risks of MACE and TVF compared to other current generation LES among NSTE-ACS patients treated with abbreviated or standard ticagrelor-based DAPT. These non-randomized findings are hypothesis-generating. Condensed abstract: Differences in clinical outcomes may exist between biodegradable polymer biolimus-eluting stents (BP-BES) and other current-generation limus-eluting stent (LES) in patients with acute coronary syndrome (ACS). We pooled individual data of about 7000 Non-ST-segment elevation ACS patients undergoing PCI and treated with ticagrelor with or without aspirin from two large randomized controlled trials (GLASSY and TWI-LIGHT). BP-BES patients derived very largely from GLASSY and other LES patients from TWILIGHT. In this population, BP-BES compared to other current generation LES, were associated with a lower 12-month risk of major adverse cardiovascular events and target-vessel failure. | Notes: | Mehran, R (corresponding author), Icahn Sch Med Mt Sinai, Med, 1 Gustav L Levy Place,Box 1030, New York, NY 10029 USA. roxana.mehran@mountsinai.org |
Keywords: | Biolimus eluting stent;Biodegradable polymer;Ticagrelor;Percutaneous coronary intervention Outcomes | Document URI: | http://hdl.handle.net/1942/40722 | ISSN: | 0167-5273 | e-ISSN: | 1874-1754 | DOI: | 10.1016/j.ijcard.2023.04.027 | ISI #: | 001015183000001 | Rights: | 2023 Elsevier B.V. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS_ A pooled analysis of GLASSY and TWILIGHT.pdf Restricted Access | Published version | 2.86 MB | Adobe PDF | View/Open Request a copy |
Biolimus-eluting vs. other limus-eluting stents.pdf | Peer-reviewed author version | 992.97 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.